The Lancet Diabetes And Endocrinology

---
name: the-lancet-diabetes-and-endocrinology
description: Use when targeting The Lancet Diabetes & Endocrinology or deciding whether a diabetes, endocrine, or metabolic study fits this venue. Encodes the journal's fit, the major-trial and population-research evidence bar, reporting-guideline and registration requirements, Lancet specialty house style, official-submission re-check, and desk-reject heuristics. Venue-fit aid only, not clinical advice.
---

# The Lancet Diabetes & Endocrinology (the-lancet-diabetes-and-endocrinology)

## Journal positioning

The Lancet Diabetes & Endocrinology is a Lancet specialty journal for high-impact
clinical and population research across diabetes, obesity, endocrine, and metabolic
medicine — type 1 and type 2 diabetes, obesity and metabolic disease, thyroid,
adrenal, pituitary, bone and mineral, and reproductive endocrinology. It favors
**major randomized trials, large prospective cohorts, and population/epidemiological
analyses with clear international clinical or policy consequence**, with a strong
emphasis on rigorous design, hard or patient-important outcomes, and generalizable
populations. Small single-center endocrine series, mechanistic/basic-science work
without a clinical endpoint, and routine biomarker-association studies are a weak fit
and belong in a broad clinical-endocrinology or basic-science venue. This skill is a
**fit / venue-selection / re-framing** aid; it is not clinical or regulatory advice and
does not replace the journal's current instructions for authors. Before submitting,
re-check the live The Lancet Diabetes & Endocrinology author instructions.

## When to trigger

- The author names The Lancet Diabetes & Endocrinology for a diabetes, endocrine, or
  metabolic clinical/population study and wants a fit/framing check.
- A trial or large cohort must be re-framed around an international, practice-changing
  diabetes or endocrine question.
- The author is choosing between The Lancet Diabetes & Endocrinology, the Journal of
  Clinical Endocrinology & Metabolism, Diabetologia, and general medicine.
- The author needs the journal's reporting-guideline, registration, and desk-reject
  expectations for metabolic/endocrine evidence.

## Scope & topic fit

- Randomized trials in diabetes pharmacotherapy, glucose-lowering and cardiovascular-/
  renal-outcome trials, and obesity/metabolic interventions.
- Large prospective cohorts and high-quality observational studies on diabetes/obesity
  burden, complications, prognosis, or treatment effect at scale.
- Endocrine trials and cohorts (thyroid, adrenal, pituitary, bone/mineral, reproductive)
  with patient-important outcomes.
- Population, epidemiological, and health-policy studies on metabolic disease with
  international or equity relevance.
- Pragmatic, implementation, and prevention trials, and well-powered diagnostic studies,
  in diabetes/endocrinology.
- Systematic reviews and meta-analyses resolving a focused, clinically consequential
  metabolic or endocrine question.

## Method & evidence bar

- Trials must be adequately powered with prespecified, patient-important primary
  outcomes (cardiovascular/renal events, mortality, body-weight or glycaemic endpoints
  with clinical anchoring); surrogate-only endpoints need strong justification.
- The applicable reporting guideline and completed checklist are expected: CONSORT for
  trials, STROBE for observational studies, PRISMA for systematic reviews, STARD for
  diagnostic accuracy.
- Trials require prospective registration; the registration number, protocol, and
  statistical-analysis plan are expected.
- Observational and Mendelian-randomization claims must address confounding, pleiotropy,
  selection bias, and missing data; causal language must match the design.
- Effect estimates need confidence intervals and absolute as well as relative measures;
  generalizability across populations and health systems should be argued.
- Multi-center, international, and registry/linkage-scale evidence strengthens fit;
  single-center metabolic series rarely clear the bar.

## Structure & house style

- Lancet specialty format with a structured summary and a Research in context /
  evidence-before-this-study panel; re-check current article types and limits on the
  live guide.
- The introduction frames the international clinical or policy gap in metabolic/endocrine
  care; the discussion states the practice consequence and limitations plainly.
- A CONSORT/STROBE/PRISMA flow diagram is expected where applicable; tables/figures
  follow Lancet statistical-reporting standards.
- The role of the funding source statement and a data-sharing statement are expected;
  appendices carry protocol, full statistical methods, and additional analyses.

## Official-submission checklist

- Before giving submission-ready advice, read `../../resources/source-basis.md` and
  `../../resources/official-source-map.md`; start from the ICMJE/EQUATOR and Lancet
  anchors, then cite the current The Lancet Diabetes & Endocrinology page you checked.
- Search the live site for "The Lancet Diabetes Endocrinology information for authors"
  and follow the current version.
- Re-check article types, structured-summary and Research in context format, and
  word/reference/figure limits.
- Confirm trial registration, the reporting checklist (CONSORT/STROBE/PRISMA/STARD),
  protocol/SAP, the role-of-funding-source statement, and data-sharing statement.
- Re-check IRB/ethics and consent, ICMJE authorship and conflict-of-interest disclosure,
  funding, and AI-use disclosure.
- If the live official instructions conflict with this skill, the official instructions
  win.

## Pre-submission self-check

- [ ] The study answers an international, practice-changing diabetes/endocrine/metabolic question.
- [ ] The primary outcome is prespecified and patient-important; the study is adequately powered.
- [ ] The correct reporting checklist (CONSORT/STROBE/PRISMA/STARD) is completed and attached.
- [ ] Trials are prospectively registered with the number in the manuscript; protocol/SAP provided.
- [ ] Confounding, pleiotropy/selection bias, and missing data are addressed; causal language matches the design.
- [ ] IRB/consent, ICMJE disclosures, role-of-funding-source, and a data-sharing statement are prepared.

## Common desk-reject triggers

- Single-center or underpowered diabetes/endocrine studies with limited generalizability and no practice change.
- Mechanistic or basic-metabolism work with no clinical endpoint, better suited to a basic-science venue.
- Surrogate-only endpoints (e.g., HbA1c change with no clinical anchoring) presented as definitive.
- Routine biomarker- or genetic-association studies without practice-changing consequence.
- Missing trial registration, protocol, or the required reporting checklist.
- Narrow scope without international clinical or policy relevance.

## Re-routing decision

- Broad clinical endocrinology (thyroid/adrenal/pituitary/bone) without practice-changing scale → `journal-of-clinical-endocrinology-and-metabolism` (Endocrine Society, broad clinical).
- Diabetes work including basic/translational science → `diabetologia` (EASD, diabetes incl. basic science).
- Population/policy framing without a clinical metabolic endpoint → `the-lancet-public-health`.
- Endocrine-related respiratory or critical-care comorbidity dominant → `the-lancet-respiratory-medicine`.
- Broad, practice-changing significance beyond the specialty → general medicine (`jama` / NEJM / The Lancet in the natural-science bundle).

## Output format

```text
[Fit] High / Medium / Low (one-line reason)
[Target] The Lancet Diabetes & Endocrinology
[Specialty tags] <2–3 closest diabetes/endocrine/metabolic topics>
[Study design / reporting guideline] <RCT-CONSORT / cohort-STROBE / review-PRISMA / diagnostic-STARD>
[Method/evidence] <power, design, registration, generalizability — does it clear the major-trial bar?>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <article type / registration / checklist / role-of-funding / ethics / disclosures>
[Re-route suggestion] <if not a fit, a better-matched venue>
```